(E)-20-guanidinoimino-5β-pregnane-3β,14β-diol | 157484-23-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (E)-20-guanidinoimino-5β-pregnane-3β,14β-diol
• 英文别名: 2-[(E)-1-[(3S,5R,8R,9S,10S,13R,14S,17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethylideneamino]guanidine
• CAS: 157484-23-6
• 化学式: C₂₂H₃₈N₄O₂
• 分子量: 390.569
• InChiKey: RSVKUSZQRGINEO-YRTBPARRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  17β-[2-(N-phenylamidino)]hydrazinomethyl-5β-androstane-3β,14β-diol 、 (E)-20-guanidinoimino-5β-pregnane-3β,14β-diol 生成 20-(2-amidino)hydrazino-5β-pregnane-3β,14β-diol
  参考文献：
  名称：

  Hydrazino and hydroxyamino-14-.beta.-hydroxyandrostane derivatives

  摘要：

  该发明描述了具有一般式(I)的肼基和羟肼基-14.beta.-羟基雄烷衍生物：##STR1## 其中符号表示.alpha.或.beta.构型，A、B、R.sup.1、R.sup.2、R.sup.3和R.sup.4在说明中给出了它们的含义，并且它们在治疗心血管疾病如心力衰竭和高血压方面的用途。

  公开号：

  US05599806A1
• 作为产物：
  描述：

  氨基胍碳酸氢盐 、 3β,14-dihydroxy-5β,14β-pregnan-20-one 在 ammonium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 氯仿 、 水 为溶剂， 生成 (E)-20-guanidinoimino-5β-pregnane-3β,14β-diol
  参考文献：
  名称：

  Hydrazono-5.beta., 14.beta.-androstane derivatives active on the

  摘要：

  本发明涉及对心血管系统活性的新17-酰肼甲基和17-酰肼基-14-β-羟基-5-β-雄烷衍生物，以及它们的制备方法和含有相同物质的用于治疗心血管疾病，如心力衰竭和高血压的药物组合物。

  公开号：

  US05538960A1

文献信息

• New hydrazono-5-beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0583606A2

  公开（公告）日：1994-02-23

  17-Hydrazonomethyl- and 17-hydrazone-14β-hydroxy-5β-androstane derivatives of general formula (I): wherein the symbols A, --- and Y have the meaning as indicated in the specification. Processes for producing these derivatives, pharmaceutical compositions containing them as well as their use are also disclosed.

  通式（I）的 17-肼甲基-和 17-腙-14β-羟基-5β-雄甾烷衍生物： 其中符号 A、---和 Y 的含义如说明书所示。此外，还公开了这些衍生物的生产工艺、含有这些衍生物的药物组合物及其用途。
• New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0659761A2

  公开（公告）日：1995-06-28

  The present invention provides 17-Iminomethylalkenyl- and 17-iminoalkyl-14β-hydroxy-5β-androstane derivatives of general formula (I): wherein: the symbol means a or configuration or a Z or E configuration; A represents (CH2)m or -(CH = CH)n-; m represents an integer number from 1 to 6; n represents an integer number from 1 to 3. R1 represents hydrogen, C2-C4 alkyl unsubstituted or substituted by NR4R5 wherein R4, R5 which may be the same or different, represent hydrogen, C1-C4 alkyl or R4 and R5 may form, taken together with the nitrogen atom, a five- or six-membered heterocyclic ring optionally containing one or more further heteroatoms selected from oxygen and nitrogen; R2 represents hydrogen or hydroxy; R3 represents NHC(=X)NR6Ry or OR8 wherein R6, R7 which may be the same or different, represent hydrogen, methyl or C2-C4 alkyl unsubstituted or substituted by NR4 R5 wherein R4 and R5 have the previously defined meanings; R8 represents hydrogen; methyl; C2-C6 alkyl, unsubstituted or substituted by one or more NR4R5 or NHC(=NH)NH2, wherein R4 and R5 have the previously defined meanings; X represents O, S or NR9; R9 represents hydrogen, methyl, C2-C4 alkyl, C2-C4 acyl or phenyl, where the C2-C4 alkyl, C2-C4 acyl are unsubstituted or substituted by NR4 R5, wherein R4 and R5 have the previously defined meanings; and R6, R7, R9 taken two by two may form, together with the heteroatoms they are linked to, and where possible, a five- or six- or seven-membered heterocyclic ring.

  本发明提供 通式(I)的17-亚甲基烯基和17-亚氨基烷基-14β-羟基-5β-雄甾烷衍生物： 其中 符号表示或构型或 Z 或 E 构型； A 代表 (CH2)m 或 -(CH = CH)n-； m 代表 1 至 6 的整数； n 代表 1 至 3 的整数。 R1 代表氢、未取代的 C2-C4 烷基或被 NR4R5 取代的 C2-C4 烷基，其中 R4、R5 可以相同或不同，代表氢、C1-C4 烷基或 R4 和 R5 可与氮原子一起形成一个五元或六元杂环，该杂环可任选含有一个或多个选自氧和氮的杂原子； R2 代表氢或羟基； R3 代表 NHC(=X)NR6Ry 或 OR8，其中 R6、R7 可以相同或不同，代表氢、甲基或未取代的 C2-C4 烷基或被 NR4 R5 取代的 C2-C4 烷基，其中 R4 和 R5 具有前面定义的含义； R8 代表氢；甲基；未被一个或多个 NR4R5 取代或取代的 C2-C6 烷基或 NHC(=NH)NH2，其中 R4 和 R5 具有前面定义的含义； X 代表 O、S 或 NR9； R9 代表氢、甲基、C2-C4 烷基、C2-C4酰基或苯基，其中 C2-C4 烷基、C2-C4酰基未被 NR4R5 取代或被 NR4R5 取代，其中 R4 和 R5 具有前面定义的含义；以及 R6、R7、R9 与它们相连的杂原子可组成五元或六元或七元杂环。
• Synthesis and Quantitative Structure−Activity Relationships of 17β-(Hydrazonomethyl)-5β-androstane-3β,14β-diol Derivatives That Bind to Na⁺,K⁺-ATPase Receptor
  作者：Luisa Quadri、Alberto Cerri、Patrizia Ferrari、Elena Folpini、Massimo Mabilia、Piero Melloni

  DOI：10.1021/jm950806n

  日期：1996.1.1

  A series of 17 beta-(hydrazonomethyl)-5 beta-androstane-3 beta,14 beta-diol derivatives was synthesized and evaluated in the displacement of [H-3]ouabain binding from Na+,K+-ATPase. The data were explored with multiple linear regression and partial least-squares to find possible quantitatives structure-activity relationships. Good correlations were found between binding to the receptor and van der Waals volumes or molar refractivities of the 17 beta-hydrazonomethyl substituents and pK(a) values of the compounds. Equivalent results were obtained using the proton affinity (calculated using MOPAC) of the hydrazone residues instead of experimental pK(a). As basicity or related electronic factors of the substituents explain a significant portion of the observed changes in the activity, an ion-pair interaction between a carboxylate residue of the enzyme and the protonated 17 beta-hydrazonomethyl group, as postulated by Thomas, plays an important role in the interaction of the ligand to the Na+,K+-ATPase receptor.
• New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardio-vascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0688786B1

  公开（公告）日：1997-08-06
• US5538960A
  申请人：——

  公开号：US5538960A

  公开（公告）日：1996-07-23